利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.033 秒)

    Antibodies to the C3d fragment of complement component 3
    3.
    发明授权
    Antibodies to the C3d fragment of complement component 3 有权

    公开(公告)号：US09815890B2

    公开(公告)日：2017-11-14

    申请号：US13805522

    申请日：2011-06-22

    申请人： V. Michael Holers ,  Joshua M. Thurman ,  Liudmila Kulik ,  Stephen Tomlinson

    发明人： V. Michael Holers ,  Joshua M. Thurman ,  Liudmila Kulik ,  Stephen Tomlinson

    IPC分类号： C07K16/28 ,  A61K39/395 ,  C07K16/18 ,  C07K14/47

    CPC分类号： C07K16/18 ,  C07K14/472 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00

    摘要： The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.

    ANTIBODIES TO THE C3d FRAGMENT OF COMPLEMENT COMPONENT 3
    5.
    发明申请
    ANTIBODIES TO THE C3d FRAGMENT OF COMPLEMENT COMPONENT 3 审中-公开
    C3d补丁组件的抗体3

    公开(公告)号：US20130078245A1

    公开(公告)日：2013-03-28

    申请号：US13589079

    申请日：2012-08-17

    申请人： V. Michael Holers ,  Joshua M. Thurman ,  Liudmila Kulik

    发明人： V. Michael Holers ,  Joshua M. Thurman ,  Liudmila Kulik

    IPC分类号： C07K16/18 ,  C07K14/47

    CPC分类号： C07K16/18 ,  C07K14/472 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00

    摘要： The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting prophylactic or therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.

    摘要翻译： 本发明涉及用于调节补体替代途径（CAP），补体经典途径（CCP），补体凝集素/甘露糖途径（CMP）或其组合的方法和材料，以及用于靶向预防性或 治疗剂可以与身体内的组织的局部区域相比，其可以以非靶向的系统方式与相同或相似的药物的给药相比，其可以更直接地将其作用发挥到预定的靶细胞或组织上，具有减少的相关系统效应。 因此，本发明的方法和材料可以允许增加功效，降低阈值有效剂量和/或降低有效维持剂量，和/或在发生频率或严重程度方面减少相关的不利或不利影响，或两者兼有。 本发明还涉及用于调节宿主体液免疫应答，特别是减少，抑制或预防宿主体液免疫应答的方法和材料。

    ANTIBODIES TO THE C3D FRAGMENT OF COMPLEMENT COMPONENT 3
    7.
    发明申请
    ANTIBODIES TO THE C3D FRAGMENT OF COMPLEMENT COMPONENT 3 有权
    C3D补丁组件的抗体3

    公开(公告)号：US20130129728A1

    公开(公告)日：2013-05-23

    申请号：US13805522

    申请日：2011-06-22

    申请人： V. Michael Holers ,  Joshua M. Thurman ,  Liudmila Kulik

    发明人： V. Michael Holers ,  Joshua M. Thurman ,  Liudmila Kulik

    IPC分类号： C07K16/18

    CPC分类号： C07K16/18 ,  C07K14/472 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00

    摘要： The present invention relates to methods and materials for modulating the complement alternative pathway (CAP), the complement classical pathway (CCP), the complement lectin/mannose pathway (CMP), or combinations thereof, as well as methods and materials for targeting diagnostic, prophylactic and therapeutic agents to localized areas of tissue within the body where they may more directly exert their effects upon the intended target cells or tissue, with reduced, associated systemic effects compared with administration of the same or similar agents in an untargeted, systemic manner. The methods and materials of the present invention may therefore allow for increased efficacy, lower threshold effective dosages and/or lower effective maintenance doses, and/or reduced associated undesired or adverse effects in terms of frequency or severity of occurrence, or both. The present invention also relates to methods and materials for modulating a host humoral immune response, especially reducing, inhibiting, or preventing a host humoral immune response.

    摘要翻译： 本发明涉及用于调节补体替代途径（CAP），补体经典途径（CCP），补体凝集素/甘露糖途径（CMP）或其组合的方法和材料，以及用于靶向诊断的方法和材料， 预防和治疗剂可以与身体内组织的局部区域直接发挥作用，与预定的靶细胞或组织相比，以相对于或相似的药物以非靶向的系统方式施用相比，具有减少的相关系统效应。 因此，本发明的方法和材料可以允许增加功效，降低阈值有效剂量和/或降低有效维持剂量，和/或在发生频率或严重程度方面减少相关的不利或不利影响，或两者兼有。 本发明还涉及用于调节宿主体液免疫应答，特别是减少，抑制或预防宿主体液免疫应答的方法和材料。